Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Ukaegbu

Internal Medicine Lake City, FL Medical Doctor

NPI 1427254283 CMS profile 830759

221 Sw Stonegate Ter Ste 101, Lake City, FL 32024

Open in the dashboard

General payments

$7,002

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Ukaegbu of Lake City, FL is reported in the CMS Open Payments database as having received $7,002 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,485 66
2024 General $1,856 87
2023 General $1,089 49
2022 General $491 30
2021 General $714 41
2020 General $791 41
2019 General $577 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Ukaegbu
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Ukaegbu were reported at $1,485. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Ukaegbu Internal Medicine median Middle half National median
2019 $577 $159 $48–$570 $163
2020 $791 $119 $33–$402 $114
2021 $714 $135 $37–$521 $132
2022 $491 $141 $42–$496 $149
2023 $1,089 $149 $45–$519 $160
2024 $1,856 $154 $47–$537 $164
2025 $1,485 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,743 79 payments
  2. Novo Nordisk Inc $732 40 payments
  3. Corcept Therapeutics $720 34 payments
  4. GlaxoSmithKline, LLC. $706 30 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $582 31 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $368 15 payments
  7. Lilly USA, LLC $328 15 payments
  8. Xeris Pharmaceuticals, Inc. $298 15 payments
  9. Amgen Inc. $229 16 payments
  10. Merck Sharp & Dohme Corporation $203 12 payments
  11. Other $1,093 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,938 338 payments
  2. Education $64 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,321 55 payments
  2. Korlym $720 34 payments
  3. Ozempic $670 37 payments
  4. TRELEGY ELLIPTA $562 24 payments
  5. RYBELSUS $533 31 payments
  6. Kerendia $368 15 payments
  7. JARDIANCE $366 21 payments
  8. AIRSUPRA $237 12 payments
  9. RECORLEV $226 11 payments
  10. Dexcom G6 Transmitter $198 6 payments
  11. Other $3,549 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 189 drugs

Part D claims

11,550

Median for Internal Medicine: 777

Drug cost

$1,258,983

Median for Internal Medicine: $73,373

Branded share of claims

29%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 224 $210,848
Ozempic Semaglutide Brand 112 $183,006
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 90 $89,453
Eliquis Apixaban Brand 106 $85,881
Mounjaro Tirzepatide Brand 46 $57,710
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 221 $46,765
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 149 $44,533
Rybelsus Semaglutide Brand 14 $34,279
Trulicity Dulaglutide Brand 23 $32,497
Jardiance Empagliflozin Brand 25 $32,234

The 10 drugs with the highest cost, of 189 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$79,275

Medicare's payments for the services billed

Medicare patients

218

Average age 73

Services billed

1,109

122 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 39%
Diabetes 38%
Ischemic heart disease 28%
Atrial fibrillation 17%
COPD 17%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $374
$374 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $192
$192 224 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $141
  • Lilly USA, LLC $42
$183 25 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $180
$180 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $179
$179 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record